Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease
The purpose of this three-year study is to test the hypothesis that solanezumab will slow the decline of perceived cognitive functions and performance of everyday activities, as compared with placebo, in persons with preclinical Alzheimer’s disease.
Subjects will receive intravenous infusions of blinded study treatment every four weeks. Subjects will undergo MRI and PET scans, and an optional LP, cognitive and physical function testing, ECGs and blood draws throughout the course of the study. Clinic visits every 12 weeks will be conducted.
At Rush University Medical Center we expect to recruit approximately 10 patients. The treatment will be assigned randomly.
In order to participate you must:
- Be 65-85 years of age
- Have a reliable study partner
You will be excluded from the study if you:
- Have serious or unstable illnesses, or do not have good venous access
- Cannot undergo MRI, PET or lumbar puncture procedures
This is a partial list of inclusion and exclusion criteria.